menu
    • menu

    Company profile for Aplagon

    NEW Drugs in Dev: 2
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Aplagon is a clinical-stage biopharmaceutical company developing first-in-class therapies for thromboinflammatory diseases. Built on pioneering research by Prof. Riitta Lassila’s group at Wihuri Research Institute in Finland, Aplagon’s lead candidate, APAC, is a heparin proteoglycan mimetic. With a strong scientific foundation, APAC is now advancing through clinical studies for two cardiovascular indications, aiming to pro...
    Aplagon is a clinical-stage biopharmaceutical company developing first-in-class therapies for thromboinflammatory diseases. Built on pioneering research by Prof. Riitta Lassila’s group at Wihuri Research Institute in Finland, Aplagon’s lead candidate, APAC, is a heparin proteoglycan mimetic. With a strong scientific foundation, APAC is now advancing through clinical studies for two cardiovascular indications, aiming to provide innovative solutions for patients with unmet medical needs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AplagonFinland Flag
    Country
    Country
    Finland
    Address
    Address
    Biomedicum Helsinki 2A Tukholmankatu 8 A, 00290 Helsinki
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://aplagon.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aplagon Doses First Patient in APAC Ph 2a Trial for PAOD/CLTI
    Aplagon Doses First Patient in APAC Ph 2a Trial for PAOD/CLTI

    13 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-13/aplagon-announces-first-patient-dosed-in-phase-2a-clinical-trial-of-apac-in-patients-with-peripheral-arterial-occlusive-disease-chronic-limb-threate

    PHARMIWEB
    13 Mar 2026
    Share Share
    Aplagon Doses First Patient in Phase 2a APAC Trial for PAOD/CLTI
    Aplagon Doses First Patient in Phase 2a APAC Trial for PAOD/CLTI

    12 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/12/3254318/0/en/Aplagon-Announces-First-Patient-Dosed-in-Phase-2a-Clinical-Trial-of-APAC-in-Patients-with-Peripheral-Arterial-Occlusive-Disease-Chronic-Limb-Threatening-Ischemia.html

    GLOBENEWSWIRE
    12 Mar 2026
    Share Share
    Aplagon Secure 7M to Advance APAC for Thrombo-Inflammatory Diseases
    Aplagon Secure 7M to Advance APAC for Thrombo-Inflammatory Diseases

    03 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2025/02/03/3019222/0/en/Aplagon-Announces-EUR-7-Million-Financing-to-Advance-its-APAC-Therapeutic-for-Thrombo-Inflammatory-Diseases-into-Phase-2A-Clinical-Trials.html

    GLOBENEWSWIRE
    03 Feb 2025
    Share Share
    Aplagon secures EUR 7 million for APAC phase 2a trials
    Aplagon secures EUR 7 million for APAC phase 2a trials

    03 Feb 2025

    // PHARMATIMES

    https://pharmatimes.com/news/aplagon-secures-eur-7-million-for-apac-phase-2a-trials/

    PHARMATIMES
    03 Feb 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search